AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 172 min read$RCKT

Shah Gaurav sold $10K of RCKT

Shah Gaurav (CEO) sold 2,837 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.38 on 2026-08-13.

Original reporting
SEC EDGAR · Shah Gaurav
Published Aug 17, 2026, 9:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RCKT
Neutral
low confidence
Mentioned
$RCKT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings and may slightly influence sentiment, but the disclosure lacks any accompanying operational or financial update.

02

Market read

A new insider-sale datapoint for RCKT, with limited trading implications absent other catalysts.

03

What to watch

Insider sales are common and frequently non-informational; traders should weigh this against any concurrent news (earnings, guidance, financing, clinical/regulatory updates) not present here.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for Rocket Pharmaceuticals, filed 2026-08-17.

Company-level read

Ticker impact

$RCKTNeutralLow confidence
Context

Rocket Pharmaceuticals CEO Shah Gaurav sold 2,837 shares in an open-market transaction at $3.3810/share, per a new Form 4 filing.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company performance, guidance, or regulatory/operational development.

Market effects

Sector

No clear sector read-through from a single small insider sale without accompanying company-specific developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a disclosed 10b5-1 plan could be interpreted as less systematic selling, but insider sales still often reflect diversification or personal liquidity needs.

Key entities

  • issuer
    Rocket Pharmaceuticals, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    Shah Gaurav

    CEO reporting an open-market sale of 2,837 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

SEP 4
$RCKTHighAI 9/10

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Rocket Pharmaceuticals (RCKT) shares fell 22% despite FDA approval of its gene therapy Kresladi for a rare pediatric disorder. The company received a Rare Pediatric Disease Priority Review Voucher. Analysts from Wedbush and LifeSci Capital maintained 'Outperform' ratings, citing the milestone and potential financial benefits. RCKT stock has dropped 53% in the past year.

stocktwits.com2 min
SEP 2
$RCKTMedAI 8/10

Rocket amended complaint alleges UWM targeted Mr. Cooper borrowers

Rocket amended its complaint against UWM, alleging UWM breached agreements by targeting Mr. Cooper borrowers for refinancing, causing prepayment rates 2.5x higher. Rocket claims $100M in damages, citing UWM's initiatives like Refi75 and KEEP. UWM denies allegations, calling them baseless. Rocket acquired Mr. Cooper for $14.2B in 2025.

housingwire.com3 min
AUG 10
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic mic

SEC EDGAR 8-K6 min
AUG 4
$RCKTMed

Rocket points to Danon gene therapy’s safety after Phase II protocol change

Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.

yahoo.com5 min
AUG 3
$RCKTMed

Why is Rocket Pharmaceuticals stock volatile today?

Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.

investing.com3 min
JUN 12
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Completion of Acquisition or Disposition of Assets

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R

SEC EDGAR 8-K2 min